AstraZeneca PLC Release: AZD9291 Shows Durable Clinical Response In Patients With Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer At The ESMO 2014 Congress

LONDON--(BUSINESS WIRE)--Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).1 The progression free survival (PFS) results are based on a 30% data maturity from 138 patients.1

Help employers find you! Check out all the jobs and post your resume.